Molecular basis for oncogenic signaling via Wnt-receptor pseudokinases

Description of the granted funding

Ovarian cancer (OC) is one of the most common gynecologic cancers that also has high mortality rate. This is due to resistant and metastatic forms of the disease that causes relapsing. Hence, there is an urgent need for new effective treatments for OC. Interestingly, it has been found that OC cells, among other types of cancer cells, have high expression of receptors that bind Wnt ligands, such as tyrosine kinase-like orphan receptor 1 and 2 (ROR1 and 2) and protein tyrosine kinase 7 (PTK7), which are not expressed at high levels in healthy adult tissues. My projects will give insight of how these Wnt-signaling receptors drive cancer progression and how by targeting their expression we could stop cancer growth. We use OC cell lines and patient-derived cells to study the oncogenic events driven by these receptors, including genes and signaling cascades they alter. In parallel, we will develop molecules that bind explicitly to these tumor-specific receptors and block their function.
Show more

Starting year

2022

End year

2026

Granted funding

Juuli Raivola Orcid -palvelun logo
278 066 €

Funder

Research Council of Finland

Funding instrument

Postdoctoral Researcher

Decision maker

Scientific Council for Biosciences, Health and the Environment
28.04.2022

Other information

Funding decision number

349787

Fields of science

Biochemistry, cell and molecular biology

Research fields

Biokemia, biofysiikka

Identified topics

cancer